Clinical trials: Temozolomide, completed
Metastatic Melanoma
Phase I/II Study of High-Dose Calcitriol Plus Temodar for Patients With Metastatic Melanoma
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00301067
- Testing
- Calcitriol, Temozolomide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Northwestern University
Brain Neoplasms, Melanoma
Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients
The goal of this clinical research study is to find the highest safe dose of lomustine (CCNU, CeeNUTM) that can be given with temozolomide (TemodarTM) and thalidomide (ThalomidTM) in the treatment of metastatic melanoma that has…
- Trial name
- NCT00527657
- Testing
- Lomustine, Temozolomide, Thalidomide
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- M.D. Anderson Cancer Center
Glioblastoma Multiforme/Anaplastic Astrocytoma
Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Anaplastic Astrocytoma
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00841555
- Testing
- temozolomide, Hypofractionated radiation therapy, Intensity-modulated radiation therapy
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Brain and Central Nervous System Tumors
Bevacizumab, Temozolomide, and External Beam Radiation Therapy as First-Line Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT01013285
- Testing
- bevacizumab, temozolomide, external beam radiation therapy
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Glioma, Astrocytoma
Temozolomide All-Case-Registered Surveillance (Designated Drug Use Investigation)(Study P05062)
The purpose of this study is to confirm the safety and efficacy of temozolomide in patients with newly diagnosed malignant glioma (concomitant with radiotherapy and then as monotherapy) and relapsed malignant glioma (as…
- Trial name
- NCT00705198
- Testing
- Temozolomide (for newly diagnosed malignant glioma), Temozolomide (for relapsed malignant glioma), Radiotherapy (for patients with newly diagnosed malignant glioma)
- Volunteers
- 1,804 people
- Sponsor
- Merck Sharp & Dohme LLC
Glioblastoma Multiforme
Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM
To test the effectiveness and safety of Optune® given concomitantly with radiation therapy (RT) and temozolomide (TMZ) in newly diagnosed GBM patients, compared to radiation therapy and temozolomide alone.
- Trial name
- EF-32 (NCT04471844)
- Testing
- Optune®
- Where
- 130 sites in United States, Austria and 9 more
- Volunteers
- 981 people
- Sponsor
- NovoCure Ltd.
Glioblastoma
Conventional Adjuvant Temozolomide With Dose Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma
This is a Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose Intensive Temozolomide in Patients with Newly Diagnosed Glioblastoma.
- Trial name
- NCT01364064
- Testing
- TMZ
- Volunteers
- 1,153 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Brain and Central Nervous System Tumors
Radiation Therapy, Arsenic Trioxide, and Temozolomide in Treating Patients With Newly Diagnosed High-Grade Glioma
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as arsenic trioxide and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the…
- Trial name
- NCT00720564
- Testing
- arsenic trioxide, temozolomide, adjuvant therapy
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- City of Hope Medical Center
Glioblastoma
Trial of Hypofractionated Radiation Therapy for Glioblastoma
This study is being done to compare standard radiation therapy with hypofractionated radiation therapy for patients with newly diagnosed glioblastoma
- Trial name
- NCT02206230
- Testing
- Hypofractionated radiation therapy, Standard radiation therapy
- Where
- Canada
- Volunteers
- 133 people
- Sponsor
- AHS Cancer Control Alberta
Brain and Central Nervous System Tumors
Temozolomide Plus Thalidomide in Treating Patients With Recurrent or Progressive Brain Tumor
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor.
- Trial name
- NCT00006358
- Testing
- temozolomide, thalidomide
- Where
- 11 sites in United States
- Volunteers
- 44 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Brain and Central Nervous System Tumors, Metastatic Cancer
Temozolomide in Treating Patients With Primary Brain Tumors or Metastatic Brain Tumors
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00547131
- Testing
- temozolomide, laboratory biomarker analysis, liquid chromatography
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- City of Hope Medical Center
Melanoma
Evaluate Safety/Tolerability Intra-Arterial Temozolomide in Patients w/Extremity Melanoma by Isolated Limb Infusion
The purpose of this study is to determine the safety profile of intra-arterial temozolomide administration during Isolated Limb Infusion (ILI) by defining the dose limiting toxicities associated with this treatment.
- Trial name
- NCT01127594
- Testing
- Temozolomide
- Where
- 3 sites in United States
- Volunteers
- 29 people
- Sponsor
- Douglas Tyler
Non-hematologic Malignancies, Metastatic Melanoma
A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients
This Phase I clinical trial is studying the side effects and best dose of ABT-888 when given together with Temozolomide (chemotherapy) in treating patients with solid tumors, including metastatic melanoma (MM), BRCA deficient…
- Conditions
- Non-hematologic Malignancies, Metastatic Melanoma, Breast Cancer, Ovarian Cancer
- Trial name
- NCT00526617
- Testing
- ABT-888, Temozolomide
- Volunteers
- 41 people
- Sponsor
- AbbVie
Brain and Central Nervous System Tumors
Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma
RATIONALE: Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide.
- Trial name
- NCT01026493
- Testing
- temozolomide 60 mg x 21 days, temozolomide 75 mg x 21 days, ABT-888 20 mg x 21 days
- Where
- 17 sites in United States
- Volunteers
- 257 people
- Sponsor
- Radiation Therapy Oncology Group
Central Nervous System Lymphoma
Nordic Study in Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma
The purpose of the study is to test the efficacy and tolerability of a multiagent chemotherapy treatment regimen without radiotherapy in patients with newly diagnosed lymphoma in the brain.
- Trial name
- NCT01458730
- Testing
- Immunochemotherapy
- Where
- Denmark
- Volunteers
- 66 people
- Sponsor
- University of Aarhus
Glioblastoma
Retrospective Evaluation of Melanocortin Receptor 4 Polymorphisms in Patients With GBM Treated With Radiochemotherapy
Glioblastoma (GBM) accounts for approximately 50% of all glioma and among these tumors, are the most malignant. The cells of origin of glioma are still undefined, but the most putative target cells include astrocytes, neural stem…
- Trial name
- GLIOMELA (NCT02458508)
- Where
- Italy
- Volunteers
- 65 people
- Sponsor
- University of Pisa
Gliosarcoma, MGMT-Unmethylated Glioblastoma
Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma
This phase II/III trial compares the usual treatment with radiation therapy and temozolomide to radiation therapy in combination with immunotherapy with ipilimumab and nivolumab in treating patients with newly diagnosed MGMT…
- Trial name
- NCT04396860
- Testing
- Contrast-enhanced Magnetic Resonance Imaging, Ipilimumab, Nivolumab
- Where
- 285 sites in United States
- Volunteers
- 159 people
- Sponsor
- National Cancer Institute (NCI)
Brain Tumor, Glioblastoma
Suberoylanilide Hydroxamic Acid (SAHA), Bevacizumab, Daily Temozolomide for Recurrent Malignant Gliomas
This is a Phase I/II open-label, single-arm study among recurrent malignant glioma patients. Patients will be treated with Vorinostat in combination with Bevacizumab (BV) (10 mg/kg) and Temozolomide (T) (50 mg/m2/day) BV is…
- Trial name
- NCT00939991
- Testing
- Vorinostst/Bevacizumab/Temozolomide
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Katy Peters
Metastatic Colorectal Cancer
NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal Cancer
This is a Phase II, multicenter, single-arm trial designed to evaluate the efficacy and safety of nivolumab (NIVO), ipilimumab (IPI) and temozolomide (TMZ) combination in 27 patients with MSS, MGMT-silenced mCRC with initial…
- Trial name
- MAYA (NCT03832621)
- Testing
- Temozolomide, Nivolumab, Ipilimumab
- Where
- Italy
- Volunteers
- 135 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Glioblastoma
Post Marketing Surveillance: Newly Diagnosed Glioblastoma Multiforme Treated With Radiotherapy/Temozolomide and Adjuvant Temozolomide (Study P04739)
The purpose of this surveillance is to collect more safety and efficacy data in "non-study" patients during concomitant and adjuvant temozolomide therapy.
- Trial name
- NCT00704808
- Testing
- Primary surgical treatment, Radiotherapy, Temozolomide
- Volunteers
- 180 people
- Sponsor
- Merck Sharp & Dohme LLC